Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots?

Stem Cells

Volumn 31, Issue 10, 2013, Pages 2033-2041

  Griffin, Matthew D ^a   Elliman, Stephen J ^b   Cahill, Emer ^c   English, Karen ^c   Ceredig, Rhodri ^a   Ritter, Thomas ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b Orbsen Therapeutics Ltd   (Ireland)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Autoimmunity; Cell therapy; Clinical trials; Immunosuppression; Inflammation; Mesenchymal stem cells

Indexed keywords

BIOMEDICINE; BONE MARROW CELL; CELL CULTURE; CELL ISOLATION; CELL KINETICS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATORY DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; REVIEW; RISK ASSESSMENT; TRANSLATIONAL RESEARCH; UNIVERSITY HOSPITAL;

AUTOIMMUNITY; CELL THERAPY; CLINICAL TRIALS; IMMUNOSUPPRESSION; INFLAMMATION; MESENCHYMAL STEM CELLS;

ADULT STEM CELLS; ANIMALS; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; GRAFT VS HOST DISEASE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGENERATIVE MEDICINE;

EID: 84887896673     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1452     Document Type: Review

References (75)

1. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
2. Caplan AI, Bruder SP Mesenchymal stem cells: Building blocks for molecular medicine in the 21st century. Trend Mol Med 2001;7:259-264.
3. Caplan AI. Why are MSCs therapeutic? New data: New insight. J Pathol 2009;217:318-324.
4. Bianco P, Cao X, Frenette PS et al. The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat Med 2013;19:35-42.
5. Griffin MD, Ryan AE, Alagesan S et al. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: What have we learned so far? Immunol Cell Biol 2013;91:40-51.
6. Le Blanc K., Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012;12:383-396.
7. Prockop DJ, Youn Oh J. Mesenchymal stem/stromal cells (MSCs): Role as guardians of inflammation. Mol Ther 2012;20:14-20.
8. Duijvestein M, Vos ACW, Roelofs H et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: Results of a phase I study. Gut 2010;59:1662-1669.
9. Le Blanc K., Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579-1586.
10. McKernan R, McNeish J, Smith D. Pharma's developing interest in stem cells. Cell Stem Cell 2010;6:517-520.
11. Tan J, Wu W, Xu X et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 2012;307:1169-1177.
12. Ciccocioppo R, Bernardo ME, Sgarella A et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011;60:788-798.
13. Hare JM, Fishman JE, Gerstenblith G et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The poseidon randomized trial. JAMA 2012;308:2369-2379.
14. Phinney DG, Sensebe L. Mesenchymal stromal cells: Misconceptions and evolving concepts. Cytotherapy 2013;15:140-145.
15. The Committee for Advanced Therapies (CAT). Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 2010;9:195-201.
16. Ancans J. Cell therapy medicinal product regulatory framework in Europe and its application for MSC based therapy development. Front Immunol 2012;3.
17. Morikawa S, Mabuchi Y, Kubota Y et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 2009;206:2483-2496.
18. Omatsu Y, Sugiyama T, Kohara H et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 2010;33:387-399.
19. Mendez-Ferrer S., Michurina TV, Ferraro F et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010;466:829-834.
20. Ding L, Saunders TL, Enikolopov G et al. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012;481:457-462.
21. Greenbaum A, Hsu Y-MS, Day RB et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 2013;495:227-230.
22. Mourcin F, Breton C, Tellier J et al. Galectin-1-expressing stromal cells constitute a specific niche for pre-BII cell development in mouse bone marrow. Blood 2011;117:6552-6561.
23. Park D, Spencer JA, Koh Bong I et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell 2012;10:259-272.
24. Battula VL, Treml S, Bareiss PM et al. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 2009; 94:173-184.
25. Maijenburg MW, Kleijer M, Vermeul K et al. The composition of the mesenchymal stromal cell compartment in human bone marrow changes during development and aging. Haematologica 2012;97:179-183.
26. Tormin A, Li O, Brune JC et al. CD146 expression on primary nonhe-matopoietic bone marrow stem cells is correlated with in situ localization. Blood 2011;117:5067-5077.
27. Crisan M, Yap S, Casteilla L et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3: 301-313.
28. Armulik A, Genové G, Betsholtz C. Pericytes: Developmental, physiological, and pathological perspectives, problems, and promises. Developmental Cell 2011;21:193-215.
29. Choi H, Lee RH, Bazhanov N et al. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-ΚB signaling in resident macrophages. Blood 2011;118:330-338.
30. English K, Ryan JM, Tobin L et al. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25High forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009;156:149-160.
31. Ge W, Jiang J, Arp J et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010;90: 1312-1320.
32. Kavanagh H, Mahon BP Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 2011;66:523-531.
33. Nemeth K, Keane-Myers A, Brown JM et al. Bone marrow stromal cells use TGF-ß to suppress allergic responses in a mouse model of ragweed-induced asthma. PNAS 2010;107:5652-5657.
34. Nemeth K, Leelahavanichkul A, Yuen PST et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogram-ming of host macrophages to increase their interleukin-10 production. Nat Med 2009;15:42-49.
35. Akiyama K, Chen C, Wang D et al. Mesenchymal-stem-cell-induced immunoregulation involves fas-ligand-/fas-mediated T cell apoptosis. Cell Stem Cell 2012;10:544-555.
36. Li Y-P, Paczesny S., Lauret E et al. Human Mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway. J Immunol 2008;180:1598-1608.
37. Zhang B, Liu R, Shi D et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 2009;113:46-57.
38. Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: Mesenchymal stem cells and macrophages move in. J Exp Med 2011; 208:421-428.
39. Ghannam S, Pène J, Torcy-Moquet G et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010;185:302-312.
40. Duffy MM, Pindjakova J, Hanley SA et al. Mesenchymal stem cell inhibition of T-helper 17 cell differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 2011;41:2840-2851.
41. Quaedackers ME, Baan CC, Weimar W et al. Cell contact interaction between adipose-derived stromal cells and allo-activated T lymphocytes. Eur J Immunol 2009;39:3436-3446.
42. Li W, Ren G, Huang Y et al. Mesenchymal stem cells: A double-edged sword in regulating immune responses. Cell Death Differ 2012; 19:1505-1513.
43. English K, Barry FP, Mahon BP Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Letters 2008;115:50-58.
44. Chiesa S, Morbelli S, Morando S et al. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. PNAS 2011;108: 17384-17389.
45. Nauta AJ, Kruisselbrink AB, Lurvink E et al. Mesenchymal stem cells inhibit generation and function of both CD34 +-derived and monocyte-derived dendritic cells. J Immunol 2006;177:2080-2087.
46. Maria Spaggiari G., Moretta L. Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol Cell Biol 2013; 91:27-31.
47. Franquesa M, Hoogduijn MJ, Bestard O et al. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol 2012;3.
48. Mantovani A. MSCs, Macrophages, and cancer: A dangerous menage-à-trois. Cell Stem Cell 2012;11:730-732.
49. Lazennec G, Jorgensen C. Concise Review: Adult multipotent stromal cells and cancer: Risk or benefit? Stem Cells 2008;26:1387-1394.
50. Wang D, Wang S, Shi C. Update on cancer related issues of mesenchymal stem cell-based therapies. Curr Stem Cell Res Ther 2012;7: 370-380.
51. Lee Ryang H., Yoon N, Reneau JC et al. Preactivation of human MSCs with TNF-a enhances tumor-suppressive activity. Cell Stem Cell 2012;11:825-835.
52. Ren G, Zhao X, Wang Y et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFa. Cell Stem Cell 2012;11:812-824.
53. Schu S, Nosov M, O'Flynn L et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012;16:2094-2103.
54. Huang X-P, Sun Z., Miyagi Y et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010;122:2419-2429.
55. Eggenhofer E, Benseler V, Kroemer A et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012;3.
56. Nystedt J, Anderson H, Tikkanen J et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells 2013;31:317-326.
57. Plock JA, Schnider JT, Schweizer R et al. Are cultured mesenchymal stromal cells an option for immunomodulation in transplantation? Front Immunol 2013;4.
58. Schlosser S, Dennler C, Schweizer R et al. Paracrine effects of mesenchymal stem cells enhance vascular regeneration in ischemic murine skin. Microvasc Res 2012;83:267-275.
59. Curley GF, Hayes M, Ansari B et al. Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax 2012;67:496-501.
60. Waszak P, Alphonse R, Vadivel A et al. Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats. Stem Cells Dev 2012;21:2789-2797.
61. Oh JY, Kim MK, Shin MS et al. The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells 2008;26:1047-1055.
62. Roddy GW, Oh JY, Lee RH et al. Action at a distance: Systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-a stimulated gene/protein 6. Stem Cells 2011;29: 1572-1579.
63. Lazarus HM, Haynesworth SE, Gerson SL et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transplant 1995;16:557-564.
64. Hoogduijn MJ, Popp FC, Grohnert A et al. Advancement of mesen-chymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 2010;90:124-126.
65. See F, Seki T, Psaltis PJ et al. Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. J Cell Mol Med 2011;15:2117-2129.
66. Cuthbert R, Boxall SA, Tan HB et al. Single-platform quality control assay to quantify multipotential stromal cells in bone marrow aspirates prior to bulk manufacture or direct therapeutic use. Cytotherapy 2012; 14:431-440.
67. Akiyama K, You YO, Yamaza T et al. Characterization of bone marrow derived mesenchymal stem cells in suspension. Stem Cell Res Ther 2012;3:40.
68. Moll G, Rasmusson-Duprez I, von Bahr L et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 2012;30:1565-1574.
69. von Bahr L., Sundberg B, Lönnies L et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012;18:557-564.
70. Galipeau J. The mesenchymal stromal cells dilemma - does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 2013;15:2-8.
71. von Bahr L., Batsis I, Moll G et al. Analysis of tissues following mes-enchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012;30: 1575-1578.
72. Dander E, Lucchini G, Vinci P et al. Mesenchymal stromal cells for the treatment of graft-versus-host disease: Understanding the in vivo biological effect through patient immune monitoring. Leukemia 2012; 26:1681-1684.
73. Li Y, Lin F. Mesenchymal stem cells are injured by complement after their contact with serum. Blood 2012;120:3436-3443.
74. Li H, Guo Z, Jiang X et al. Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells 2008;26: 2531-2541.
75. Prasad VK, Lucas KG, Kleiner GI et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011;17: 534-541.